News | Remote Monitoring | March 14, 2016

New Biotronik Insertable Cardiac Monitor Available in the U.K. and Ireland

Implantable device provides accurate daily transmission of cardiac electrical data for arrhythmia detection

Biotronik, BioMonitor 2, AF remote monitoring, atrial fibrillation, U.K. and Ireland

March 14, 2016 — Biotronik announced that its BioMonitor 2 heart monitor is now available for patients in the United Kingdom. The insertable device allows highly accurate and reliable continuous detection of cardiac electrical events.

The monitor is indicated for patients suffering from unexplained syncope, and to detect atrial fibrillation (AF). Diagnosing the irregular heartbeat condition AF is notoriously difficult, as is finding the root cause of syncope — a condition where the patient passes out due to decreased blood flow to the brain. If left untreated, both can be life threatening.

In response, BioMonitor 2 can be inserted under the skin of the patient in a simple procedure. It then records all cardiac electrical events. Data from the device is transmitted directly to the physician via Biotronik Home Monitoring, where they are given an accurate map of the heart’s activity right on their computer screen.

“AF is often so sporadic and unpredictable that it is sometimes impossible to diagnose at the time the patient has symptoms,” commented Riyaz Kaba, M.D., from Ashford and St Peter’s Hospitals, Surrey, and St George’s Hospital, London. “It is similar with syncope. The patient can hardly choose to faint when they are hooked up to an ECG just so we can find out what’s causing it. But, because BioMonitor 2 is always on and always recording, we can see exactly what’s going on with their cardiac rhythm in these precise moments. It’s really unprecedented and the accuracy of the readings has exceeded our expectations. We get a clear picture very early on, meaning necessary treatment can begin earlier.”

As well as its diagnostic benefits, the device has been designed with the patient anatomy in mind. “The insertion procedure is easy for both doctor and patient. It only takes a few minutes,” explained Kaba. “The monitor adapts to the patient’s anatomy, and they’re satisfied with the overall cosmetic result.”

BioMonitor 2 also has Biotronik ProMRI technology and is approved for full-body magnetic resonance imaging (MRI) scans at both the usual 1.5 and ultra-high 3.0 tesla strength. Its average battery life is four years, topping the industry standard by a year.

For more information: www.biotronik.com


Related Content

News | Atrial Fibrillation

Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to ...

Home November 19, 2024
Home
News | Atrial Fibrillation

Oct. 18, 2024 — The Heart Rhythm Society (HRS) Board of Trustees unanimously approved the formation of Heart Rhythm ...

Home October 21, 2024
Home
News | Atrial Fibrillation

Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San ...

Home September 11, 2024
Home
News | Atrial Fibrillation

July 24, 2024 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home July 24, 2024
Home
News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
Subscribe Now